Mannitol Injection, Solution
Product Images NDC 0990-7715

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Mannitol (NDC 0990-7715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Icu Medical Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Mannitol 01)

FDA Label Image

Principal Display Panel (250 mL Bag Label)

Principal Display Panel (250 mL Bag Label)
This is a description of a 250 mL container of 20% Mannitol Injection, USP, manufactured by 1CU Medical Inc., containing 50 g/250 mL (200 mg/mL) of mannitol. Each 100 mL of the injection contains 20 grams of mannitol and may contain sodium bicarbonate for pH adjustment. The solution is sterile and nonpyrogenic, and is for intravenous use only. Additives may be incompatible, so users should consult with a pharmacist, if available, and mix the additives thoroughly and aseptically. The solution should be administered intravenously within a specific range of temperature and should be discarded if unused. If the solution is not clear, the container is damaged or crystals form, the solution should not be used. The container is a single-dose container and must not be used in series connections. The text contains a warning about contraindication in severe renal impairment.*
FDA Label Image

Principal Display Panel (500 mL Bag Label)

Principal Display Panel (500 mL Bag Label)
This is a description of 20% Mannitol Injection, USP contained in a single-dose container of 500mL for intravenous use. It contains Mannitol at a concentration of 200mg/mL with sodium bicarbonate for pH adjustment. Each 100mL contains 20 grams of Mannitol. The solution is sterile, non-pyrogenic, and has a calculated osmolality of 1098 mOsmol/L. It is indicated for use with careful inspection and must not be used in series connections. If crystals form, the solution should be agitated to dissolve and administered intravenously at 30 to 37 °C (86 to 986 °F). The solution may have incompatibilities with additives, and it is recommended to consult with a pharmacist when introducing additives to the solution. The dosage information can be found in the insert, and this solution is contraindicated in severe renal impairment.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.